Home Newsfeeds UBS Downgrades Immunovant to Neutral, Lowers Price Target to $5

UBS Downgrades Immunovant to Neutral, Lowers Price Target to $5

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $7 to $5.

byBenzinga Newsdesk

September 26, 2022

1 minute read

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $7 to $5.

Raymond James Maintains Strong Buy on Enterprise Prods Partners, Raises Price Target to $32

By Benzinga Newsdesk

August 4, 5:41 AM

Raymond James analyst Justin Jenkins maintains Enterprise Prods Partners (NYSE:EPD) with a Strong Buy and raises the price target from $31 to $32.

EPD

Movers
News

What’s Going On With Crypto Mining Company Marathon Digital Holdings?

By Ryan Gustafson

January 17, 4:54 PM

Marathon Digital Holdings, Inc. (NASDAQ: MARA) shares are trading lower on Wednesday.

MARA

Truist Securities Maintains Buy on Global Payments, Raises Price Target to $145

By Benzinga Newsdesk

February 13, 8:21 AM

Truist Securities analyst Andrew Quail maintains Global Payments (NYSE:GPN) with a Buy and raises the price target from $135 to $145.

GPN

HP’s Challenges Unlikely To Ease Anytime Soon, Bear Analyst Says After Q3 Print

By Priya Nigam

August 31, 4:55 PM

HP Inc’s (NYSE: HPQ) downbeat third-quarter revenue miss and reduction in fourth-quarter guidance were the largest of their kind in over five years, according to Morgan Stanley.

HPQ

UBS Downgrades Immunovant to Neutral, Lowers Price Target to $5

Related Posts

Raymond James Maintains Strong Buy on Enterprise Prods Partners, Raises Price Target to $32

What’s Going On With Crypto Mining Company Marathon Digital Holdings?

Truist Securities Maintains Buy on Global Payments, Raises Price Target to $145

HP’s Challenges Unlikely To Ease Anytime Soon, Bear Analyst Says After Q3 Print